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1. Synopsis 23 
Background: Vancomycin is recommended for ventriculitis. However, penetration into the 24 
CNS is relatively poor. 25 
Objectives: To investigate the population pharmacokinetics of vancomycin serum and CSF in 26 
critical care patients with proven or suspected CNS infections from neurosurgical procedures. 27 
Patients and methods: This was an observational pharmacokinetic study in critical care 28 
patients with proven or suspected CNS infections receiving intravenous vancomycin. Multiple 29 
blood and intraventricular CSF samples were collected. Population pharmacokinetic analysis 30 
and simulation were undertaken with ADAPT5 and Pmetrics.  31 
Results: 187 blood and CSF samples were collected from 21 patients. The median (range) 32 
Cmax and Cmin concentrations in serum were 25.67 (10.60-50.78) and 9.60 (4.46-23.56) mg/L, 33 
respectively, with a median daily dose of 2500 (500-4000) mg. The corresponding median 34 
concentrations in CSF was 0.65 (<0.24-3.83) mg/L and 0.58 (<0.24-3.95) mg/L, respectively. 35 
The median AUC0-24 in serum and CSF was 455.09 mg*h/L and 14.10 mg*h/L, respectively. A 36 
three-compartment linear population pharmacokinetic model best fitted the observed data. 37 
Vancomycin demonstrated poor penetration into CSF, with a median CSF/serum ratio of 3% 38 
and high inter-subject pharmacokinetic variability of its penetration. 39 
Conclusion: Therapeutic drug monitoring (TDM) in both serum and CSF and higher daily 40 
doses may be an option to ensure adequate trough levels and to optimize patient therapy. 41 
Novel dosing strategies designed to reduce renal toxicity, such as administration by continuous 42 
infusion, should be investigated in further clinical studies to avoid antibiotic underexposure in 43 
CSF. 44 
 45 
2. Introduction 46 
Gram-positive cocci, especially Staphylococcus spp., are the leading cause of surgical site 47 
infections resulting from neurosurgical procedures.1 Despite the development of novel 48 
antibiotics active against Gram-positive pathogens, vancomycin generally remains the 49 
standard of care, particularly of methicillin resistant MRSA and methicillin resistant 50 
Staphylococcus epidermidis (MRSE).2 Furthermore, vancomycin is used in combination with 51 
meropenem as empiric antibiotic therapy in critical care patients with infections of the CNS 52 
such as meningitis or ventriculitis.1 However, in the absence of meningeal inflammation the 53 
penetration into CSF of vancomycin is hampered by its large molecular weight and 54 
hydrophilicity.3, 4 Recent data suggest there is highly variable penetration of vancomycin into 55 
the CSF.5 Relatively little is known about the pharmacokinetics (PK) of vancomycin in the CSF 56 
of patients with ventriculitis.5, 6 57 
A serum AUC/MIC value of 400 in serum is often used as a pharmacodynamic target.2 There 58 
is less clarity about the relevant drug exposure at the target site of infection (e.g. the CSF for 59 
critical care patients with proven or suspected CNS infections) and the regimens required to 60 
achieve these targets. Conventionally used regimens of 500 mg every 6 h (q6h) or 1 g every 61 
12 h (q12h) have little evidence supporting their efficacy in specific populations particularly 62 
critically ill patients.7 Guidelines recommend 30-60 mg/kg/day vancomycin for meningitis and 63 
ventriculitis to ensure sufficient CSF concentrations.1, 2 Due to very few studies in meningitis 64 
patients an alternative agent should be considered, if vancomycin MIC is ≥1 mg/L.1 However, 65 
drug as well as disease factors, such as the presence of meningeal inflammation and the 66 
integrity of the blood-liquor barrier, are important to consider when devising dosing strategies.3, 67 
4, 6 The meninges in ventriculitis are typically normal or only minimally inflamed.3, 4, 6 Therefore, 68 
penetration into the CNS in patients with ventriculitis should not be extrapolated from other 69 
patient populations.3, 4, 6 70 
The purpose of this study was to investigate the population pharmacokinetics of vancomycin 71 
in serum and CSF in critical care patients with external ventricular drains (EVD) and proven or 72 
suspected ventriculitis. Such an analysis is fundamental to characterize the inter-individual 73 
variability of vancomycin concentrations in CSF and to further investigate optimal vancomycin 74 
regimens for patients with ventriculitis. 75 
 76 
3. Patients and methods 77 
3.1. Study design and population 78 
This prospective observational PK study was conducted at the intensive care unit of Munich 79 
Ludwig-Maximilians-University (LMU) Hospital, Germany between April 2014 and January 80 
2016. Patients older than 18 years of age who required an EVD and in whom a proven or 81 
suspected EVD-associated ventriculitis developed were enrolled in the study. The diagnosis 82 
of ventriculitis was defined as a positive CSF culture combined with clinical signs of infection.8 83 
Suspected ventriculitis was defined by abnormal CSF parameters, such as low CSF glucose 84 
levels (<50% of serum glucose), high CSF protein (>50 mg/dL) or CSF pleocytosis, combined 85 
with clinical signs of infection in the absence of a positive CSF culture.8 Patients were excluded 86 
if they were under 18 years of age or death within 72 h was expected.  87 
3.2. Ethics  88 
The trial was conducted in accordance with the Declaration of Helsinki. Ethical approval was 89 
obtained from the university ethics committee (registration number 111-14). Written informed 90 
consent was obtained from all patients or a legally authorized representative before enrolment. 91 
3.3. Study procedures 92 
All included patients received vancomycin (Vancomycin CP®, Hikma Pharma, Germany) as a 93 
prolonged infusion over 4 h, targeting trough concentrations of 10-15 mg/L in serum. Serial 94 
blood and CSF sampling occurred for initial dose and steady state. Blood samples (4 mL) were 95 
collected using the indwelling arterial catheter just before the start of the infusion (trough 96 
concentration; Cmin) and after the end of the infusion (peak concentration; Cmax). CSF samples 97
(1 mL) were collected using the indwelling EVD nearest to the site of insertion (3 mL volume 98 
to sampling location) simultaneously with each blood sample just before the start of the infusion 99 
(cerebrospinal fluid concentration at serum trough concentration [Ctrough]) and after the end of 100 
the infusion (cerebrospinal fluid concentration 4 h after serum trough concentration [Cafter 4h]). 101 
Samples were centrifuged for 5 minutes at 4000 rpm and stored at −80 °C within 45 minutes 102 
after sample collection for a maximum of 4 weeks until the measurement of drug. Serum and 103 
CSF concentrations of vancomycin were analysed using an in vitro chemiluminescent micro 104 
particle immunoassay (ARCHITECT iVancomycin assay, Abbott; measuring range: 0.24 mg/L-105 
100.00 mg/L). For CSF concentrations of vancomycin, spiked CSF samples were carried out 106 
on a regular basis in addition to the routine validation process. Only vancomycin total 107 
concentration (bound plus unbound) was measured.  108 
Additional data were obtained from the medical record including weight, height, serum 109 
creatinine, bilirubin, serum C-reactive protein (CRP), serum interleukin-6 (IL-6), serum 110 
procalcitonin (PCT), serum leucocytes, CSF cells, CSF erythrocytes, CSF IL-6, CSF glucose, 111 
CSF protein, CSF drain in 24 h, Simplified Acute Physiology II Score (SAPS II), SOFA Score, 112 
Glasgow Coma Score (GCS), and dexamethasone therapy.  113 
3.4. Population pharmacokinetic analysis 114 
A three-compartment model with zero order infusion for vancomycin was fitted to the study 115 
data.9 The structural model took the form: 116 
(1) dXC/dt =R(t) –  (SCL/Vc + kcp + kcb ) x XC + kpc x XP + kbc x XCSF 117 
(2) dXP/dt = kcp x XC – kpc x XP 118 
(3) dXCSF/dt = kcb x XC – kbc x XCSF 119 
The three equations above describe the rate of change of vancomycin (mg) in the central (1), 120 
peripheral (2) and CSF (3) compartments, respectively. The equation elements are defined in 121 
figure 1 legend. Equation (1) describes the rate of change of the amount of vancomycin (in 122 
milligrams) in the central compartment (XC). Equation (2) describes the rate of change of the 123 
amount of vancomycin (in milligrams) in the peripheral compartment (XP). Equation (3) 124 
describes the rate of change of the amount of vancomycin (in milligrams) in the CSF (XCSF). A 125 
schematic representation of the structural model is shown in Figure 1.  126 
We used the Pmetrics package v. 1.5.0.10 to model the concentration-time data for 127 
vancomycin, simulate from the model, generate plots and perform standard data summaries 128 
and statistical tests. The observed data were weighted by the inverse of individual error 129 
coefficients that were obtained using the maximum likelihood estimator in ADAPT 5. Additional 130 
process noise such as errors in sampling time or dosing was modelled using gamma as a 131 
multiplicative error term in Pmetrics. 132 
3.5. Population pharmacokinetic model diagnostics 133 
Acceptance of the final model was evaluated by the log-likelihood, the coefficient of 134 
determination (r2) of the linear regression and visual inspection of diagnostic scatterplots, 135 
where model predictions were generated either by the median population parameter values or 136 
by the medians of each subject’s individual Bayesian posterior parameter value distributions. 137 
3.6. Population pharmacokinetic covariate screening 138 
The impact of weight, height, CrCL, bilirubin, serum CRP, serum IL-6, serum PCT, serum 139 
leucocytes, CSF cells, CSF erythrocytes, CSF IL-6, CSF glucose, CSF protein, CSF drain in 140 
24 h, SAPS II, SOFA Score, GCS and dexamethasone therapy as covariates were initially 141 
assessed by visual inspection. For that reason, graphical representation in Pmetrics of each 142 
covariate versus population parameter was performed to evaluate for inclusion in the final 143 
model.  144 
 145 
3.7. Other pharmacokinetic calculations 146 
Cmax, Cmin, Cafter 4h, and Ctrough are the observed values. AUC in serum and CSF was calculated 147 
using the Bayesian estimates from each patient using the trapezoidal rule that is implemented 148 
within Pmetrics. We divided each subject’s cumulative AUC by the total time in hours and 149 
multiplied the result by 24 to estimate the daily average AUC (AUC0–24). The correlation 150 
between these values was assessed using Pearson’s test. Penetration of vancomycin into 151 
CSF was described using the CSF/serum ratio, which was calculated by dividing the 152 
cumulative AUC in CSF by the cumulative AUC in serum. Half-life was calculated using 153 
transfer rate constants. Creatinine clearance (CrCL) was calculated using the Cockcroft-Gault 154 
equation.11 All calculations were performed using IBM SPSS Statistics version 23.0 software 155 
(IBM, Armonk, NY, USA).  156 
3.8. Assessment of vancomycin concentration in CSF 157 
We performed simulation of 3000 patients using Pmetrics to compare different dosing 158 
regimens in this study population (1000 mg every 12 h, 2000 mg every 12 h with each 159 
administered as a 4 h infusion. Additionally, the outcome of 4000 mg, and 6000 mg 160 
administered as a continuous infusion was examined). A PTA in CSF was analysed using 161 
Pmetrics targeting vancomycin concentrations of 0.25 mg/L, 0.5 mg/L, 1 mg/L, and 2 mg/L.  162 
4. Results 163 
The study included 196 blood samples and 186 CSF samples from 21 patients. Detailed 164 
demographic characteristics are presented in Table 1. One CSF sample was excluded from 165 
the study because of concentration 3 times the standard deviation (n=1). Serum samples were 166 
excluded because of uncertain sample collection time (n=2). 167 
The study population was relatively young (median age 52 years, range 46–80 years) and had 168 
well-preserved renal function on the day of inclusion (median CrCL 120.1 ml/min, range 52.3-169 
217.6 ml/min). The median (range) SAPS II score was 47 (13–62). All patients received 170 
meropenem therapy in addition to vancomycin. Seven patients (33.3%) received concomitant 171 
fosfomycin for 7 days, although one (4.8%) of them also received rifampicin, which then was 172 
replaced by fosfomycin. Patient 1 additionally received dexamethasone during the first 2 days, 173 
and patient 14 additionally received dexamethasone during the first 5 days.  174 
The most frequent neurological disease was subarachnoid haemorrhage, which was 175 
diagnosed in 17 (81.0%) patients. In the remaining four patients, an EVD was placed for 176 
intracranial bleeding (4.8%), tumour (9.5%) or traumatic brain injury (4.8%). A total of 20 177 
patients (95.2%) were CSF culture-negative, and one patient (4.8%) had a positive culture for 178 
Pseudomonas aeruginosa. In serum, median Cmax (range) was 25.67 (10.60-50.78) mg/L and 179 
median (range) Cmin was 9.60 (4.46-23.56) mg/L. In CSF, median Cmax (range) was 0.65 180 
(<0.24-3.83) mg/L and median Cmin 0.59 (<0.24-3.95) mg/L. In total, 64 CSF samples were 181 
below the detection limit. Median daily dose of vancomycin was 2500 (500-4000) mg 182 
administered in two divided doses. Individual observed vancomycin concentrations and doses 183 
are shown in Table S1, available as supplementary data at JAC Online. CrCL on sample days 184 
ranged from 52.3 to 122.5 mL/min (median CrCL 122.5 mL/min). The median AUC0-24 in CSF 185 
was 14.10 mg*h/L and in serum 455.09 mg*h/L. The median values for the AUC0-24 in CSF and 186 
serum ranged from 2.64 to 81.30 mg*h/L and 277.35 to 521.02 mg*h/L, respectively. The 187 
median CSF/serum ratio (range) was 0.03 (0.01-0.18). There was no statistically significant 188 
correlation between the AUC in serum and CSF (r=-0.112, p=0.629).  Individual AUC0-24 and 189 
penetration results are shown in Table S2, available as supplementary data at JAC Online. 190 
4.1. Pharmacokinetic model building 191 
The fit of the mathematical model to the observed data was acceptable according to visual 192 
inspection of the observed-versus-predicted plots and r2 of the observed-versus-predicted 193 
values (r2 = 0.930 in serum, r2 = 0.579 in CSF) (Figure S1, available as supplementary data at 194 
JAC Online). Individual PK results in serum and CSF obtained by Pmetrics for the PK model 195 
are shown in Table S2. The mean, median, and SD for the population parameters identified 196 
by Pmetrics for the PK model are shown in Table 2. Population parameter value covariance 197 
matrix are shown in Table S3, available as supplementary data at JAC Online. Values of these 198 
pharmacokinetic parameters in the population were estimated by using all data, replacing data 199 
below the quantification limit with the value QL/2, where QL is the quantification limit.12 No 200 
covariate relationships could be supported for any of the model parameters. 201 
4.2. Assessment of vancomycin concentration in CSF 202 
Simulated vancomycin concentration–time profiles in serum and CSF of each regimen are 203 
shown in Figure 2. The simulated AUC in steady-state of vancomycin 1000 mg every 12 h is 204 
shown in Figure 3.  Vancomycin concentrations in CSF greater than or equal to 0.25 mg/L, 0.5 205 
mg/L, 1 mg/L, and 2 mg/L were exceeded in 99.8%, 96.0%, 61.4%, and 0.1 % of simulated 206 
patients, respectively for a regimen of 2000 mg every 12 h. Similarly, these thresholds were 207 
exceeded in 87.2%, 57.8%, 5.6%, and 0% of simulated patients receiving 1000 mg every 12 208 
h. With continuous infusion vancomycin concentrations in CSF greater than or equal to 0.25 209 
mg/L, 0.5 mg/, 1 mg/L, and 2 mg/L were exceeded in 100.0%, 100.0%, 96.8%, and 25.6% of 210 
patients receiving a daily dose of 6000 mg, and in 100.0%, 97.4%, 67.4%, and 0.3% receiving 211 
a daily dose of 4000 mg.  212 
5. Discussion 213 
To our knowledge, this is the first population PK study of vancomycin concentrations in serum 214 
and CSF in critical care patients with proven or suspected ventriculitis. We found that 215 
penetration of vancomycin into CSF is poor, with a median penetration ratio of only 3% and a 216 
large intersubject variability in CSF vancomycin concentration as well as resultant CSF/serum 217 
ratios. However, PK variability in CSF was not explained by any covariates. Our study suggests 218 
the additional need for therapeutic drug monitoring of vancomycin in CSF if vancomycin MIC 219 
is ≥1 mg/L to avoid treatment failures due to underexposure in CSF and to identify patients for 220 
a change of therapy.  221 
It is generally accepted, that the drug penetration into CSF is indicative of the transport across 222 
the choroid plexus at the blood–CSF barrier.13 Therefore, a separate CSF compartment was 223 
considered in our model and linked to the central compartment by a first-order process. Our 224 
PK model suggest that vancomycin penetration (median t1/2cb 9 h) into CSF is slower than CSF 225 
clearance (median t1/2bc 8 h) (Table S2). This is consistent with other studies in ventriculitis 226 
patients14 as well as in non-inflamed meninges.15 CSF drain volume from the EVD can be high 227 
in patients with hydrocephalus after placing the EVD. Therefore, loss through an EVD could 228 
be an additional route of drug elimination from CSF.16 However, a CSF drain over the course 229 
of treatment was not found to influence the pharmacokinetics of vancomycin. The high 230 
apparent volume of CSF reflects the relatively low CSF concentrations compared with serum. 231 
VCSF is not a physiological CSF volume; it is merely a scalar that explains the concentration 232 
observed in the CSF. Previous studies identified CSF albumin level as a determinant of CSF 233 
vancomycin concentration.16-18 However, albumin level as a predictor of the blood brain barrier 234 
is not validated in patients with external drain.19 This is because an increased CSF albumin is 235 
influenced by blood in the CSF through subarachnoid bleeding or intracerebral bleeding. 236 
Furthermore, CSF albumin may vary with time and patients in previous studies were included 237 
after neurosurgery for only 72 h.16-18 Since the majority of EVD-related infections occurs within 238 
the first 5 to 14 days after insertion, CSF albumin level as a surrogate guide to CSF vancomycin 239 
concentration should not be extrapolated to ventriculitis patients.20, 21 In our study, all patients 240 
were at least five days post neurosurgery.  241 
Vancomycin does not show universally low penetration into CSF. While penetration in inflamed 242 
meninges is reportedly as high as 81%, penetration into CSF in normal or mildly infected 243 
meninges are conflicting varying from 0 – 36%.5 Other studies suggest that neurosurgical 244 
procedures may damage the blood-brain-barrier and facilitate penetration of vancomycin into 245 
CSF.16, 18 Although, many studies have estimated CSF penetration using a single point 246 
estimates of serum and CSF vancomycin concentrations. Vancomycin CSF-to-serum ratios in 247 
six patients with ventriculitis ranged from 5 to 17%, with patients achieving CSF concentrations 248 
of 1.1–6 mg/L.5 This variability is consistent with the PK variability in our study population with 249 
penetration ranging from 1 to 18%. No covariate predicted vancomycin CSF penetration, as 250 
reported by Beach and colleagues.5 Furthermore, there was no statistically significant 251 
correlation between plasma AUC and CSF AUC, which poses challenges for the use of serum 252 
TDM to ensure therapeutic concentrations in CSF. However, 34% of our CSF samples showed 253 
very low vancomycin concentrations. Patients with ventriculitis may benefit from continuous 254 
infusion to ensure higher CSF concentrations of vancomycin.15, 22 Continuous infusion may 255 
also simplify therapeutic drug monitoring (TDM) in daily routine because concentration 256 
measurement is time-independent and facilitates calculation of the AUC. As reported by Neely 257 
and colleagues, more than approximately 50% of the interindividual variability in the AUC are 258 
not explained by trough concentration.23 Further clinical studies are warranted to investigate 259 
the pharmacokinetics, safety and efficacy of vancomycin infusions for the treatment of 260 
ventriculitis.  261 
From a PD point of view, MRSA and MRSE are the most challenging pathogens in nosocomial 262 
CNS infection.1 It is unclear which PK-PD target should be used to optimise the outcome for 263 
infections within the CNS.6, 24 Data from an experimental pneumococcal meningitis model 264 
suggest peak concentration of vancomycin 4 times the MBC for a maximal bacterial killing rate 265 
in CSF.25 An AUC/MIC value of 400 has been established as the PK - PD target in serum 266 
based on in-vitro and animal data.2 In CSF of our patients, an AUC/MIC target of 400 is hardly 267 
exceeded. More work is required to better understand PD targets at the site of infection for 268 
patients with ventriculitis. In our study, 61.4% of the simulated patients with 2000 mg every 12 269 
h as a prolonged infusion exceeded CSF trough concentrations of 1 mg/L assuming all drug 270 
in the CSF is unbound, whereas 96.0% exceeded 0.5 mg/L.  271 
Patients in our study were generally young without any measured renal dysfunction on day of 272 
inclusion (median CrCL 122 mL/min, Table 1) in contrast to the renal function in other studies 273 
(mean CrCL 90 mL/min 26, 56 mL/min and 78 mL/min 23). In concordance vancomycin 274 
clearance in serum (6 L/h) was higher comparing to other PK studies in critically ill patients 275 
(4.6 L/h 26, 3.0 L/h 23). In severe infections and/or deep infections trough concentrations in 276 
serum of 15-20 mg/L (AUC of 600-800 mg/L*h) are recommended.1, 2 Young patients with 277 
augmented renal clearance presented in this study (8 of 21 patients with CLCr ≥ 130 mL/min, 278 
Table S1) are at high risk of insufficient concentrations of vancomycin with conventional dosing 279 
regimens. Therefore, in critical care patients with CNS infections caused by MRSA or MRSE 280 
with an MIC ≥ 1 mg/L, the standard dosing regimen of vancomycin 2000 every 12 h as a 281 
prolonged infusion is unlikely to ensure adequate CSF concentrations. However, TDM in CSF 282 
may identify patients with sufficient vancomycin concentrations in CSF. In those displaying 283 
ARC, increased frequency of dosing or continuous infusion with serum AUC of 600-720 mg/L*h 284 
may be more appropriate.27 In addition, continuous infusion may reduce renal toxicity 285 
especially with high doses.28 Alternatives like linezolid, daptomycin or sulfmethoxazol-286 
trimethoprim should be considered in patients with high serum concentrations (AUC up to 800 287 
mg/L*h) and low CSF concentrations (<1 mg/L).1  288 
There are several limitations of our study. First, the study was relatively small, which may have 289 
hampered robust estimates of the extent of PK variability and the identification of covariates 290 
that may have explained some of the observed variance. CrCL was estimated, because the 291 
measurement is not routinely performed in routine clinical care. Secondly, pharmacokinetic 292 
data were not adjusted for protein binding, because we measured the total concentration in 293 
serum and CSF. Due to negligible protein levels in CSF compared to serum and that protein 294 
binding of vancomycin in not high, CSF concentrations might be free concentrations for 295 
vancomycin. However, protein binding of vancomycin in the CSF is currently unknown. Third, 296 
the ethical approval allowed two samples per day and of the 186 samples, 64 (34%) were 297 
reported below the limit of quantification which might have an impact on the final parameter 298 
estimates from the population PK model.  299 
In conclusion, this is the largest PK study of critical care patients with proven or suspected 300 
ventriculitis. Population pharmacokinetic modeling approach is a useful tool to predict drug 301 
exposure under different dosage regimens. We found, that vancomycin showed low 302 
penetration into CSF. However, because of inter-subject variability of vancomycin TDM in both 303 
serum and CSF and higher daily doses may be an option to ensure adequate trough levels at 304 
the target site of infection and to identify patients for a change of therapy. Novel dosing 305 
strategies of vancomycin should be investigated in further clinical studies in ventriculitis 306 
therapy such as administration by continuous infusion in order to reduce renal toxicity and to 307 
avoid antibiotic underexposure in the context of augmented elimination or impaired target site 308 
penetration.  309 
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 395 
Age (years), median (range) 52 (46-80) 
Weight (kg), median (range) 76 (55-105) 
Body mass index, median (range) 25.95 (20-33) 
Sex, %male/%female 52,4%/47,6% 
CrCL on day of inclusion (mL/min), median (range) 120.1 (52.3-217.6) 
CRP in serum on day of inclusion (mg/dL), median (range) 3.1 (0.4-36.7) 
Interleukin 6 in serum on day of inclusion (pg/mL), median (range) 13.7 (2.4-274.0) 
CSF drain in 24 h on day of inclusion (mL), median (range) 183 (21-360) 
Interleukin 6 in CSF on day of inclusion (pg/mL), median (range) 3398 (140-24522) 
Cells in CSF on day of inclusion (/uL), median (range) 503 (4-2894) 
Protein in CSF on day of inclusion (mg/dL), median (range) 10.7 (1.3-30.3) 
Glucose in CSF on day of inclusion (mg/dL), median (range) 72 (47-126) 
Glucose CSF/serum ratio on day of inclusion, median (range) 0.55 (0.38-0.99) 
SAPS II on day of inclusion, median (range) 47 (13-62) 
SAPS II on day of exclusion, median (range) 32 (13-61) 
 396 
Table 1 Patient characteristics 397 
CrCL: Estimated creatinine clearance (calculated using the Cockroft–Gault equation 11); CRP: 398 
C-reactive protein; SAPS II: Simplified Acute Physiology II Score 399 
 400 
 
 
mean ± SD median 95% CI 
SCL (L/h) 6.11 ±2.16 5.89 5.19-7.23 
Vc (L) 24.33 ±11.47 25.40 16.42-28.59 
kcp (h-1) 1.44 ±1.22 1.18 0.61-1.86 
kpc (h-1) 2.38 ±1.47 2.47 1.56-3.08 
kcb (h-1) 0.18 ±0.23 0.07 0.03-0.18 
kbc (h-1) 0.12 ±0.10 0.09 0.06-0.12 
VCSF (L) 828.51 ±203.78 819.43 
731.77-
999.97 
 401 
Table 2 Population pharmacokinetic mean and median parameters of vancomycin obtained 402 
by Pmetrics 403 
SCL: clearance in L/h; Vc: apparent volume of distribution of the central compartment in L; 404 
VCSF: apparent volume of distribution of the cerebrospinal fluid compartment in L; kcp, kpc, kbc, 405 
kcb: linear transfer rate constants in h-1 406 
 407 
 408 
SOFA Score on day of inclusion, median (range) 6 (1-12) 
SOFA Score on day of exclusion, median (range) 2.5 (0-8) 
30-day mortality 0 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
Figure 1 Structural model 418 
XC is the total amount of vancomycin (mg) in the central compartment. R(t) is the zero-order-419 
infusion of vancomycin into the central compartment (mg/h). SCL is the clearance of 420 
vancomycin from the central compartment (L/h) with a volume Vc (L). XP is the total amount of 421 
vancomycin (mg) in the peripheral compartment with a volume Vp(L). kcp, kpc, kbc and kcb in h-1 422 
represent first-order transfer constants connecting the various compartments. The CSF 423 
compartment (XCSF) has an apparent CSF volume (VCSF; given in litres).   424 
XC in VC 
central 
XP in VP 
peripheral 
XCSF in VCSF 
brain 
kcp 
kpc 
kcb 
kbc 
R(t) 
SCL 
 425 
Figure 2 Comparison of different dosing regimens as prolonged infusions over 4 h or 426 
continuous infusion (CI) using the pharmacokinetic model 427 
Median time course of vancomycin concentrations simulated in serum and CSF over four days 428 
without loading dose. Targeted vancomycin trough concentrations in CSF were 0.25 mg/L, 0.5 429 
mg/L, 1 mg/L, and 2 mg/L. Targeted vancomycin trough concentration in serum were 15-20 430 
mg/L for intermittent administration. This figure appears in color in the online version of JAC 431 
and in black and white in the print version of JAC. 432 
 433 
 434 
Figure 3 Simulated AUC in steady-state (AUC0-24) of vancomycin 435 
Simulation of 3000 patients with vancomycin 1000 mg every 12 h as prolonged infusion using 436 
the pharmacokinetic model. 437 
